Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 8/20 | 0.63 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.63 |
| ▸ | CDK2 | P24941 | 3/20 | 0.62 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.62 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.62 |
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22167182 | 0.78 | MGLL (0.54) | — | |
| SCHEMBL31680549 | 0.78 | MMP2 (0.54) | — | |
| SCHEMBL30398090 | 0.78 | FLT3 (1.00) | FLT3MAP4K1CDK2CCNA2CCNA1 | |
| SCHEMBL951125 | 0.78 | FLT3 (1.00) | FLT3MAP4K1CDK2CCNA2CCNA1 | |
| SCHEMBL30695135 | 0.77 | FLT3 (0.73) | FLT3MAP4K1CDK2CCNA2CCNA1 | |
| SCHEMBL29176630 | 0.77 | FLT3 (0.73) | FLT3MAP4K1CDK2CCNA2CCNA1 | |
| SCHEMBL29176618 | 0.77 | FLT3 (0.73) | FLT3MAP4K1CDK2CCNA2CCNA1 | |
| SCHEMBL953507 | 0.77 | FLT3 (0.73) | FLT3MAP4K1CDK2CCNA2CCNA1 | |
| SCHEMBL29176629 | 0.77 | FLT3 (1.00) | FLT3MAP4K1CDK2CCNA2CCNA1 | |
| SCHEMBL30695127 | 0.77 | FLT3 (0.73) | FLT3MAP4K1CDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | disclosed |
| WO-2005014554-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS MAPKAP KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | CCNC, CDK1, CDK7 | FLT3 164/4885MAP4K1 909/4885CDK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.